Every day, more than 115 people in the United States die after overdosing on opioids…
Isn’t it time your family had a safer choice?
Roughly 21 to 29 percent of patients prescribed opioids for chronic pain misuse them1
Between 8 and 12 percent develop an opioid use disorder2-4
An estimated 4 to 6 percent who misuse prescription opioids transition to heroin2-4
Opioid overdoses increased 30% from July 2016 through September 2017 in 52 areas in 45 states5
Innovative Pain Management Solutions Without the Risk of Opioid Abuse or Addiction
This opioid issue has become a public health crisis with devastating consequences including increases in opioid misuse and related overdoses. Rilento is rethinking acute and chronic pain management using the biology of the healing process to design tailored time release compositions that address the multi-factor contributions to pain, without relying on addictive opioids.
(1) Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576. doi:10.1097/01.j.pain.0000460357.01998.f1.
(2) Muhuri PK, Gfroerer JC, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. CBHSQ Data Rev. August 2013.
(3) Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years. JAMA Psychiatry. 2014;71(7):821-826. doi:10.1001/jamapsychiatry.2014.366.
(4) Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend. 2016;160:127-134. doi:10.1016/j.drugalcdep.2015.12.026.
(5) Vivolo-Kantor, AM, Seth, P, Gladden, RM, et al. Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses--United States, July 2016-September 2017. Centers for Disease Control and Prevention
Copyright © 2017-2018 Rilento Pharma, LLC